DK1442058T3 - Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler - Google Patents

Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler

Info

Publication number: DK1442058T3
Authority: DK; Denmark
Prior art keywords: destruction; conditions requiring; treating tumors; cell removal; requiring cell
Prior art date: 2001-11-16

Application number

DK02779063T

Other languages

Danish (da)

English (en)

Inventor

Paul Averback

Jack Gemmell

Original Assignee

Nymox Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-16

Filing date

2002-11-18

Publication date

2006-12-04

2002-11-18 Application filed by Nymox Corp filed Critical Nymox Corp

2006-12-04 Application granted granted Critical

2006-12-04 Publication of DK1442058T3 publication Critical patent/DK1442058T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Neurology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychiatry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Addiction (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)

DK02779063T 2001-11-16 2002-11-18 Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler DK1442058T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33147701P	2001-11-16	2001-11-16

Publications (1)

Publication Number	Publication Date
DK1442058T3 true DK1442058T3 (da)	2006-12-04

Family

ID=23294135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02779063T DK1442058T3 (da)	2001-11-16	2002-11-18	Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler

Country Status (22)

Country	Link
US (5)	US7317077B2 (ru)
EP (1)	EP1442058B1 (ru)
JP (2)	JP4717349B2 (ru)
KR (4)	KR20050044471A (ru)
CN (1)	CN100509846C (ru)
AT (1)	ATE333467T1 (ru)
AU (1)	AU2002342463B2 (ru)
BR (1)	BRPI0213786B8 (ru)
CA (1)	CA2467053C (ru)
CY (1)	CY1107578T1 (ru)
DE (1)	DE60213274T2 (ru)
DK (1)	DK1442058T3 (ru)
EA (1)	EA007203B1 (ru)
ES (1)	ES2269775T3 (ru)
IL (2)	IL161591A0 (ru)
MX (1)	MXPA04004489A (ru)
NO (1)	NO332842B1 (ru)
NZ (1)	NZ532721A (ru)
PL (1)	PL207591B1 (ru)
PT (1)	PT1442058E (ru)
WO (1)	WO2003044053A2 (ru)
ZA (1)	ZA200403624B (ru)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7317077B2 (en) *	2001-11-16	2008-01-08	Nymox Pharmaceutical Corporation	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE202004021953U1 (de)	2003-09-12	2013-06-19	Vessix Vascular, Inc.	Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material
US20090232866A1 (en) *	2003-10-07	2009-09-17	Mariann Pavone-Gyongyosi	Oligopeptides as coating material for medical products
BRPI0509495A2 (pt) *	2004-02-06	2016-10-11	Nymox Corp	anticorpo humanizado
US8396548B2 (en)	2008-11-14	2013-03-12	Vessix Vascular, Inc.	Selective drug delivery in a lumen
US9713730B2 (en)	2004-09-10	2017-07-25	Boston Scientific Scimed, Inc.	Apparatus and method for treatment of in-stent restenosis
CN100427502C (zh) *	2005-06-09	2008-10-22	南京大学	抗肿瘤寡肽及其制备方法和应用
KR20080110765A (ko)	2006-02-28	2008-12-19	니목스 코포레이션	종양 및 세포의 제거 또는 파괴를 필요로 하는 기타 상태의치료에 효과적인 펩티드
BRPI0708737A2 (pt) *	2006-03-10	2011-06-14	Nymox Corp	mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
US8019435B2 (en)	2006-05-02	2011-09-13	Boston Scientific Scimed, Inc.	Control of arterial smooth muscle tone
US20080027005A1 (en) *	2006-07-31	2008-01-31	Paul Averback	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2008049082A2 (en)	2006-10-18	2008-04-24	Minnow Medical, Inc.	Inducing desirable temperature effects on body tissue
EP2455036B1 (en)	2006-10-18	2015-07-15	Vessix Vascular, Inc.	Tuned RF energy and electrical tissue characterization for selective treatment of target tissues
JP5559539B2 (ja)	2006-10-18	2014-07-23	べシックス・バスキュラー・インコーポレイテッド	身体組織に望ましい温度作用を誘発するシステム
CN102271603A (zh)	2008-11-17	2011-12-07	明诺医学股份有限公司	得知或未得知组织形态的选择性能量积累
JP5625043B2 (ja)	2009-04-13	2014-11-12	ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチＴｈｅＦｅｉｎｓｔｅｉｎＩｎｓｔｉｔｕｔｅｆｏｒＭｅｄｉｃａｌＲｅｓｅａｒｃｈ	低温誘導性ｒｎａ結合タンパク質（ｃｉｒｐ）を阻害することによる炎症性疾患の治療
AU2011238925B2 (en)	2010-04-09	2016-06-16	Vessix Vascular, Inc.	Power generating and control apparatus for the treatment of tissue
US9192790B2 (en)	2010-04-14	2015-11-24	Boston Scientific Scimed, Inc.	Focused ultrasonic renal denervation
US8473067B2 (en)	2010-06-11	2013-06-25	Boston Scientific Scimed, Inc.	Renal denervation and stimulation employing wireless vascular energy transfer arrangement
US9155589B2 (en)	2010-07-30	2015-10-13	Boston Scientific Scimed, Inc.	Sequential activation RF electrode set for renal nerve ablation
US9463062B2 (en)	2010-07-30	2016-10-11	Boston Scientific Scimed, Inc.	Cooled conductive balloon RF catheter for renal nerve ablation
US9408661B2 (en)	2010-07-30	2016-08-09	Patrick A. Haverkost	RF electrodes on multiple flexible wires for renal nerve ablation
US9084609B2 (en)	2010-07-30	2015-07-21	Boston Scientific Scime, Inc.	Spiral balloon catheter for renal nerve ablation
US9358365B2 (en)	2010-07-30	2016-06-07	Boston Scientific Scimed, Inc.	Precision electrode movement control for renal nerve ablation
US8974451B2 (en)	2010-10-25	2015-03-10	Boston Scientific Scimed, Inc.	Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en)	2010-10-27	2015-12-29	Boston Scientific Scimed, Inc.	RF renal denervation catheter with multiple independent electrodes
US9028485B2 (en)	2010-11-15	2015-05-12	Boston Scientific Scimed, Inc.	Self-expanding cooling electrode for renal nerve ablation
US9089350B2 (en)	2010-11-16	2015-07-28	Boston Scientific Scimed, Inc.	Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9668811B2 (en)	2010-11-16	2017-06-06	Boston Scientific Scimed, Inc.	Minimally invasive access for renal nerve ablation
US9326751B2 (en)	2010-11-17	2016-05-03	Boston Scientific Scimed, Inc.	Catheter guidance of external energy for renal denervation
US9060761B2 (en)	2010-11-18	2015-06-23	Boston Scientific Scime, Inc.	Catheter-focused magnetic field induced renal nerve ablation
US9192435B2 (en)	2010-11-22	2015-11-24	Boston Scientific Scimed, Inc.	Renal denervation catheter with cooled RF electrode
US9023034B2 (en)	2010-11-22	2015-05-05	Boston Scientific Scimed, Inc.	Renal ablation electrode with force-activatable conduction apparatus
US20120157993A1 (en)	2010-12-15	2012-06-21	Jenson Mark L	Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
US9220561B2 (en)	2011-01-19	2015-12-29	Boston Scientific Scimed, Inc.	Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US9579030B2 (en)	2011-07-20	2017-02-28	Boston Scientific Scimed, Inc.	Percutaneous devices and methods to visualize, target and ablate nerves
US9186209B2 (en)	2011-07-22	2015-11-17	Boston Scientific Scimed, Inc.	Nerve modulation system having helical guide
WO2013055826A1 (en)	2011-10-10	2013-04-18	Boston Scientific Scimed, Inc.	Medical devices including ablation electrodes
WO2013055815A1 (en)	2011-10-11	2013-04-18	Boston Scientific Scimed, Inc.	Off -wall electrode device for nerve modulation
US9420955B2 (en)	2011-10-11	2016-08-23	Boston Scientific Scimed, Inc.	Intravascular temperature monitoring system and method
US9364284B2 (en)	2011-10-12	2016-06-14	Boston Scientific Scimed, Inc.	Method of making an off-wall spacer cage
EP2768568B1 (en)	2011-10-18	2020-05-06	Boston Scientific Scimed, Inc.	Integrated crossing balloon catheter
WO2013058962A1 (en)	2011-10-18	2013-04-25	Boston Scientific Scimed, Inc.	Deflectable medical devices
WO2013070724A1 (en)	2011-11-08	2013-05-16	Boston Scientific Scimed, Inc.	Ostial renal nerve ablation
WO2013074813A1 (en)	2011-11-15	2013-05-23	Boston Scientific Scimed, Inc.	Device and methods for renal nerve modulation monitoring
US9119632B2 (en)	2011-11-21	2015-09-01	Boston Scientific Scimed, Inc.	Deflectable renal nerve ablation catheter
US9265969B2 (en)	2011-12-21	2016-02-23	Cardiac Pacemakers, Inc.	Methods for modulating cell function
AU2012358143B2 (en)	2011-12-23	2015-06-11	Boston Scientific Scimed, Inc.	Expandable balloon or an electrode pad with a heat sensing device
WO2013101452A1 (en)	2011-12-28	2013-07-04	Boston Scientific Scimed, Inc.	Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en)	2011-12-29	2015-06-09	Boston Scientific Scimed, Inc.	Off-wall electrode device and methods for nerve modulation
WO2013169927A1 (en)	2012-05-08	2013-11-14	Boston Scientific Scimed, Inc.	Renal nerve modulation devices
US10321946B2 (en)	2012-08-24	2019-06-18	Boston Scientific Scimed, Inc.	Renal nerve modulation devices with weeping RF ablation balloons
WO2014043687A2 (en)	2012-09-17	2014-03-20	Boston Scientific Scimed, Inc.	Self-positioning electrode system and method for renal nerve modulation
US10549127B2 (en)	2012-09-21	2020-02-04	Boston Scientific Scimed, Inc.	Self-cooling ultrasound ablation catheter
US10398464B2 (en)	2012-09-21	2019-09-03	Boston Scientific Scimed, Inc.	System for nerve modulation and innocuous thermal gradient nerve block
JP6074051B2 (ja)	2012-10-10	2017-02-01	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	血管内神経変調システム及び医療用デバイス
US9956033B2 (en)	2013-03-11	2018-05-01	Boston Scientific Scimed, Inc.	Medical devices for modulating nerves
WO2014143571A1 (en)	2013-03-11	2014-09-18	Boston Scientific Scimed, Inc.	Medical devices for modulating nerves
US9808311B2 (en)	2013-03-13	2017-11-07	Boston Scientific Scimed, Inc.	Deflectable medical devices
WO2014150553A1 (en)	2013-03-15	2014-09-25	Boston Scientific Scimed, Inc.	Methods and apparatuses for remodeling tissue of or adjacent to a body passage
US10265122B2 (en)	2013-03-15	2019-04-23	Boston Scientific Scimed, Inc.	Nerve ablation devices and related methods of use
JP6139772B2 (ja)	2013-03-15	2017-05-31	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	電極パッドと共に使用するための制御ユニットおよび漏電を推定するための方法
WO2014205399A1 (en)	2013-06-21	2014-12-24	Boston Scientific Scimed, Inc.	Medical devices for renal nerve ablation having rotatable shafts
JP2016523147A (ja)	2013-06-21	2016-08-08	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	同乗型電極支持体を備えた腎除神経バルーンカテーテル
US9707036B2 (en)	2013-06-25	2017-07-18	Boston Scientific Scimed, Inc.	Devices and methods for nerve modulation using localized indifferent electrodes
JP6204579B2 (ja)	2013-07-01	2017-09-27	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	腎神経アブレーション用医療器具
CN105377170A (zh)	2013-07-11	2016-03-02	波士顿科学国际有限公司	具有可伸展电极组件的医疗装置
WO2015006480A1 (en)	2013-07-11	2015-01-15	Boston Scientific Scimed, Inc.	Devices and methods for nerve modulation
WO2015010074A1 (en)	2013-07-19	2015-01-22	Boston Scientific Scimed, Inc.	Spiral bipolar electrode renal denervation balloon
US10342609B2 (en)	2013-07-22	2019-07-09	Boston Scientific Scimed, Inc.	Medical devices for renal nerve ablation
US10695124B2 (en)	2013-07-22	2020-06-30	Boston Scientific Scimed, Inc.	Renal nerve ablation catheter having twist balloon
EP4049605A1 (en)	2013-08-22	2022-08-31	Boston Scientific Scimed Inc.	Flexible circuit having improved adhesion to a renal nerve modulation balloon
CN105555218B (zh)	2013-09-04	2019-01-15	波士顿科学国际有限公司	具有冲洗和冷却能力的射频(rf)球囊导管
US10952790B2 (en)	2013-09-13	2021-03-23	Boston Scientific Scimed, Inc.	Ablation balloon with vapor deposited cover layer
EP3049438B1 (en)	2013-09-24	2018-07-25	The Feinstein Institute for Medical Research	Peptides inhibiting cold-inducible rna binding protein activity
WO2015057521A1 (en)	2013-10-14	2015-04-23	Boston Scientific Scimed, Inc.	High resolution cardiac mapping electrode array catheter
US11246654B2 (en)	2013-10-14	2022-02-15	Boston Scientific Scimed, Inc.	Flexible renal nerve ablation devices and related methods of use and manufacture
EP3057520A1 (en)	2013-10-15	2016-08-24	Boston Scientific Scimed, Inc.	Medical device balloon
US9770606B2 (en)	2013-10-15	2017-09-26	Boston Scientific Scimed, Inc.	Ultrasound ablation catheter with cooling infusion and centering basket
CN105636538B (zh)	2013-10-18	2019-01-15	波士顿科学国际有限公司	具有柔性导线的球囊导管及其使用和制造的相关方法
JP2016534842A (ja)	2013-10-25	2016-11-10	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	除神経フレックス回路における埋め込み熱電対
CN105899157B (zh)	2014-01-06	2019-08-09	波士顿科学国际有限公司	抗撕裂柔性电路组件
JP6325121B2 (ja)	2014-02-04	2018-05-16	ボストンサイエンティフィックサイムド，インコーポレイテッドＢｏｓｔｏｎＳｃｉｅｎｔｉｆｉｃＳｃｉｍｅｄ，Ｉｎｃ．	双極電極上の温度センサの代替配置
US11000679B2 (en)	2014-02-04	2021-05-11	Boston Scientific Scimed, Inc.	Balloon protection and rewrapping devices and related methods of use
US20160215031A1 (en) *	2015-01-27	2016-07-28	Nymox Pharnaceutical Corporation	Method of treating disorders requiring destruction or removal of cells
US10078207B2 (en)	2015-03-18	2018-09-18	Endochoice, Inc.	Systems and methods for image magnification using relative movement between an image sensor and a lens assembly
US20160361380A1 (en)	2015-06-12	2016-12-15	Nymox Corporation	Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CA3029064A1 (en) *	2015-06-29	2017-01-05	The University Of British Columbia	Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
US11628202B2 (en) *	2015-07-24	2023-04-18	Nymox Corporation	Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en)	2016-06-17	2019-01-22	Nymox Corporation	Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en)	2016-07-28	2019-01-08	Nymox Corporation	Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en)	2016-09-07	2020-01-14	Nymox Corporation	Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en)	2017-03-01	2019-07-02	Nymox Corporation	Compositions and methods for improving sexual function
US10835538B2 (en)	2018-03-28	2020-11-17	Nymox Corporation	Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en)	2018-08-23	2020-02-27	Nymox Corporation	Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en)	2019-05-13	2022-03-22	Nymox Corporation	Method of treating lower urinary tract symptoms with fexapotide triflutate
US11298400B2 (en)	2019-05-13	2022-04-12	Nymox Corporation	Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US20200360466A1 (en)	2019-05-13	2020-11-19	Nymox Corporation	Method of improving lower urinary tract symptoms
US11331374B2 (en)	2019-07-31	2022-05-17	Nymox Corporation	Focal treatment of prostate cancer
US11231421B2 (en)	2019-07-31	2022-01-25	Nymox Corporation	Methods of treating multifocal cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US594863A (en) *		1897-12-07		Otto p
US5169933A (en) *	1988-08-15	1992-12-08	Neorx Corporation	Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5948634A (en)	1988-12-21	1999-09-07	The General Hospital Coporation	Neural thread protein gene expression and detection of alzheimer's disease
EP0378924B1 (en)	1988-12-21	1996-11-13	The General Hospital Corporation	Detection of neurological disease or dysfunction
JPH06256387A (ja)	1991-06-14	1994-09-13	Suetsuna Yoko	新規なペプチド、その製法およびそれを有効成分とする血圧降下剤
ATE312348T1 (de)	1993-04-20	2005-12-15	Gen Hospital Corp	Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
FR2757486B1 (fr)	1996-12-24	1999-03-26	Sanofi Sa	Receptacle de conditionnement de deux produits pouvant s'ecouler et maintenus separes avant d'etre melanges pour utilisation
KR20000075748A (ko)	1997-02-26	2000-12-26	마빈 씨. 구트리	알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
US6238667B1 (en) *	1997-09-19	2001-05-29	Heinz Kohler	Method of affinity cross-linking biologically active immunogenic peptides to antibodies
CA2335986A1 (en) *	1998-06-26	2000-01-06	Simeng Suy	Use of tempo and tempo derivatives for inducing cell death
US7125957B1 (en) *	1998-09-30	2006-10-24	Riken	VPR mutant protein and its encoding gene having apoptosis-inducing action
AU2373800A (en) *	1998-12-11	2000-06-26	Incyte Pharmaceuticals, Inc.	Neuron-associated proteins
MXPA01006998A (es) *	1999-01-11	2002-05-06	Leadd Bv	Uso de agentes inductores de apoptosis en el tratamiento de enfermedades (auto) inmunitarias.
EP1161446A1 (en)	1999-03-12	2001-12-12	Human Genome Sciences, Inc.	50 human secreted proteins
AU3628600A (en)	1999-03-19	2000-10-09	Human Genome Sciences, Inc.	46 human secreted proteins
CA2368281A1 (en)	1999-03-26	2000-10-05	Craig A. Rosen	50 human secreted proteins
CA2368927A1 (en)	1999-03-26	2000-10-05	Craig A. Rosen	45 human secreted proteins
AU6745700A (en)	1999-03-26	2000-11-02	Human Genome Sciences, Inc.	49 human secreted proteins
TW555566B (en)	1999-11-16	2003-10-01	Unilever Nv	Cosmetic compositions containing anise extract and retinoids
WO2001040521A2 (en)	1999-11-30	2001-06-07	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CN1300779A (zh)	1999-12-22	2001-06-27	上海博德基因开发有限公司	一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh)	1999-12-23	2001-06-27	上海生元基因开发有限公司	新的人神经元线蛋白及其编码序列
EP1307488A2 (en)	2000-06-26	2003-05-07	Millennium Pharmaceuticals, Inc.	A human calcium channel protein and uses thereof
US6783969B1 (en)	2001-03-05	2004-08-31	Nuvelo, Inc.	Cathepsin V-like polypeptides
DK1392347T3 (da) *	2001-05-16	2005-12-12	Nymox Corp	Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner
BR0209990A (pt) *	2001-05-25	2004-06-29	Nymox Corp	Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
US7192929B2 (en) *	2001-07-19	2007-03-20	Nymox Corporation	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) *	2001-11-16	2008-01-08	Nymox Pharmaceutical Corporation	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

2002
- 2002-11-15 US US10/294,891 patent/US7317077B2/en not_active Expired - Fee Related
- 2002-11-18 JP JP2003545688A patent/JP4717349B2/ja not_active Expired - Fee Related
- 2002-11-18 KR KR1020047007366A patent/KR20050044471A/ko not_active Application Discontinuation
- 2002-11-18 IL IL16159102A patent/IL161591A0/xx unknown
- 2002-11-18 EA EA200400632A patent/EA007203B1/ru not_active IP Right Cessation
- 2002-11-18 DK DK02779063T patent/DK1442058T3/da active
- 2002-11-18 ES ES02779063T patent/ES2269775T3/es not_active Expired - Lifetime
- 2002-11-18 PT PT02779063T patent/PT1442058E/pt unknown
- 2002-11-18 PL PL370891A patent/PL207591B1/pl unknown
- 2002-11-18 AU AU2002342463A patent/AU2002342463B2/en not_active Ceased
- 2002-11-18 KR KR1020127024763A patent/KR20120123573A/ko not_active Application Discontinuation
- 2002-11-18 CN CNB028228014A patent/CN100509846C/zh not_active Expired - Fee Related
- 2002-11-18 KR KR1020107026566A patent/KR101375026B1/ko not_active Expired - Fee Related
- 2002-11-18 EP EP02779063A patent/EP1442058B1/en not_active Expired - Lifetime
- 2002-11-18 WO PCT/CA2002/001757 patent/WO2003044053A2/en active Application Filing
- 2002-11-18 MX MXPA04004489A patent/MXPA04004489A/es active IP Right Grant
- 2002-11-18 CA CA2467053A patent/CA2467053C/en not_active Expired - Fee Related
- 2002-11-18 BR BRPI0213786A patent/BRPI0213786B8/pt not_active IP Right Cessation
- 2002-11-18 KR KR1020147006037A patent/KR20140044399A/ko not_active Ceased
- 2002-11-18 AT AT02779063T patent/ATE333467T1/de active
- 2002-11-18 DE DE60213274T patent/DE60213274T2/de not_active Expired - Lifetime
- 2002-11-18 NZ NZ532721A patent/NZ532721A/en not_active IP Right Cessation
2004
- 2004-04-22 IL IL161591A patent/IL161591A/en not_active IP Right Cessation
- 2004-05-04 NO NO20041844A patent/NO332842B1/no not_active IP Right Cessation
- 2004-05-12 ZA ZA2004/03624A patent/ZA200403624B/en unknown
- 2004-10-12 US US10/920,313 patent/US7408021B2/en not_active Expired - Lifetime
2006
- 2006-10-17 CY CY20061101487T patent/CY1107578T1/el unknown
2008
- 2008-07-11 US US12/171,462 patent/US8293703B2/en not_active Expired - Fee Related
2009
- 2009-06-15 US US12/484,696 patent/US7745572B2/en not_active Expired - Lifetime
2011
- 2011-01-24 JP JP2011011764A patent/JP5357196B2/ja not_active Expired - Fee Related
2012
- 2012-10-11 US US13/649,632 patent/US8569446B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ532721A (en)	2007-05-31
AU2002342463B2 (en)	2008-09-04
JP2011135876A (ja)	2011-07-14
JP4717349B2 (ja)	2011-07-06
BRPI0213786B8 (pt)	2021-05-25
US20030166569A1 (en)	2003-09-04
US7745572B2 (en)	2010-06-29
US20090022743A1 (en)	2009-01-22
US20050032704A1 (en)	2005-02-10
EA200400632A1 (ru)	2004-10-28
NO332842B1 (no)	2013-01-21
NO20041844L (no)	2004-07-06
CY1107578T1 (el)	2013-03-13
BRPI0213786B1 (pt)	2019-01-02
WO2003044053A3 (en)	2003-12-11
US7408021B2 (en)	2008-08-05
JP5357196B2 (ja)	2013-12-04
AU2002342463A1 (en)	2003-06-10
DE60213274T2 (de)	2007-10-31
PL370891A1 (en)	2005-05-30
IL161591A0 (en)	2004-09-27
KR20140044399A (ko)	2014-04-14
CN100509846C (zh)	2009-07-08
BR0213786A (pt)	2004-11-09
CA2467053C (en)	2013-05-07
EP1442058B1 (en)	2006-07-19
IL161591A (en)	2010-02-17
US20090286742A1 (en)	2009-11-19
PT1442058E (pt)	2006-12-29
US8293703B2 (en)	2012-10-23
EP1442058A2 (en)	2004-08-04
KR20050044471A (ko)	2005-05-12
DE60213274D1 (de)	2006-08-31
ATE333467T1 (de)	2006-08-15
JP2005521383A (ja)	2005-07-21
US20130040900A1 (en)	2013-02-14
WO2003044053A2 (en)	2003-05-30
US8569446B2 (en)	2013-10-29
PL207591B1 (pl)	2011-01-31
KR20120123573A (ko)	2012-11-08
ZA200403624B (en)	2005-12-28
KR20110003552A (ko)	2011-01-12
MXPA04004489A (es)	2004-11-29
CA2467053A1 (en)	2003-05-30
KR101375026B1 (ko)	2014-03-17
ES2269775T3 (es)	2007-04-01
EA007203B1 (ru)	2006-08-25
US7317077B2 (en)	2008-01-08
CN1589279A (zh)	2005-03-02

Publication	Publication Date	Title
DK1442058T3 (da)	2006-12-04	Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler
DK1417228T3 (da)	2007-06-04	Peptider der er effektive til behandling af tumorer og andre tilstande som kræver fjernelse eller destruktion af celler
BR0209990A (pt)	2004-06-29	Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DK0912176T3 (da)	2003-01-13	Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
DE69921156D1 (de)	2004-11-18	Verwendung von 5ht-6 antagonisten zur behandlung adhd
DK1368054T3 (da)	2008-02-04	Anvendelse af neurale trådproteiner til behandling af tumorer
DE60036555D1 (de)	2007-11-08	Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
ATE479705T1 (de)	2010-09-15	Reduzierter slam abhängiger zell eintritt
NO20040221L (no)	2004-03-19	Peptider til fjerning eller destruksjon av celler
DE60233572D1 (de)	2009-10-15	Ozonbehandlung von lignocellulose substraten
EP1714979A3 (en)	2007-04-25	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1847550A3 (en)	2008-01-09	Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells